CorMedix Inc.
CRMDCorMedix Inc. is a healthcare company focused on developing and commercializing medical therapies for the prevention and containment of infections in hospital settings, particularly through its flagship product, Neutrolin, a patented antimicrobial solution used in central venous catheters to reduce bloodstream infections.
Company News
The American Kidney Fund hosted its third annual Patient Access Initiative Summit focusing on innovative kidney care technologies, AI applications, and addressing barriers to kidney disease prevention and treatment.
CorMedix completed enrollment in a Phase III clinical trial for REZZAYO, a drug aimed at preventing fungal infections in patients undergoing blood and marrow transplantation. Topline results are expected in Q2 2026, with potential FDA approval for prophylaxis treatment.
CRMD earnings call for the period ending March 31, 2024.
The mean of analysts' price targets for CorMedix (CRMD) points to a 135.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Analysts say these are penny stocks to buy. Do you agree? The post 5 Penny Stocks To Buy According To Analysts, Targets Up To 353% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
